Figma's IPO yesterday proves there has to be a better process to price these public offerings.If not, companies will find alternative paths into the public market. https://t.co/9z6RqkPcbe ...

Core Viewpoint - Oxford Square Capital Corp. has announced a public offering of $65 million in unsecured notes with a 7.75% interest rate, maturing on July 31, 2030, with the option for early redemption starting July 31, 2027 [1][2]. Group 1: Offering Details - The offering is expected to close on August 7, 2025, and includes an option for underwriters to purchase an additional $9.75 million in notes [2]. - The notes will be listed on the NASDAQ Global Select Market under the trading symbol "OXSQH" [2]. Group 2: Use of Proceeds - The net proceeds from the offering will be used to repay existing indebtedness, acquire investments, and for general corporate purposes [3]. Group 3: Company Overview - Oxford Square Capital Corp. is a publicly-traded business development company that primarily invests in syndicated bank loans and, to a lesser extent, in debt and equity tranches of collateralized loan obligation (CLO) vehicles [6].

Core Viewpoint - Abivax SA has successfully closed a public offering of 11,679,400 American Depositary Shares (ADSs), raising approximately $747.5 million, which will support its operations and clinical trials through 2027 [1][2]. Group 1: Offering Details - The public offering included the full exercise of the underwriters' option, resulting in gross proceeds of approximately $747.5 million, or €637.5 million, before expenses [1]. - Estimated net proceeds from the offering, after deducting underwriting commissions and expenses, are approximately $700.3 million, equivalent to €597.2 million [1]. - The offering was managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Group 2: Financial Outlook - The company anticipates that the net proceeds, along with existing cash and cash equivalents, will finance operations into the fourth quarter of 2027, providing a 12-month cash runway post-NDA submission for Ulcerative Colitis, contingent on positive Phase 3 trial results [2]. Group 3: Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response for chronic inflammatory diseases, with its lead drug candidate, obefazimod (ABX464), currently in Phase 3 trials for ulcerative colitis [5].

Core Viewpoint - Abivax SA has announced a public offering of American Depositary Shares (ADSs) priced at $64.00 per ADS, aiming to raise approximately $650 million to support its clinical development efforts [1][9][10]. Offering Details - The offering consists of 10,156,000 ADSs, each representing one ordinary share with a nominal value of €0.01 [1]. - The offering price reflects a 21.0% premium over the volume weighted average price of the ordinary shares on Euronext Paris over the last three trading sessions prior to pricing [2]. - The offering is managed by Leerink Partners, Piper Sandler & Co., and Guggenheim Securities, with LifeSci Capital as the lead manager [3]. Financial Proceeds - The gross proceeds from the offering are expected to be approximately $650 million, or €554 million, before deducting expenses [9]. - If the underwriters' option to purchase additional shares is fully exercised, total gross proceeds could reach approximately $747.5 million, or €637.5 million [10]. Use of Proceeds - The company plans to use the net proceeds to fund clinical development for its lead drug candidate, obefazimod, targeting ulcerative colitis and Crohn's disease, as well as for general corporate purposes [11][16]. - Specific allocations include approximately $140 million to $185 million for ulcerative colitis, and $30 million to $65 million for Crohn's disease [16]. Closing and Lock-up - The offering is expected to close on July 28, 2025, subject to customary conditions [6]. - Company board members and executive officers are subject to a 60-day lock-up period following the final prospectus supplement [13]. Dilution Impact - The issuance of ADSs will result in a dilution of approximately 16.0% of the company's share capital on a non-diluted basis, increasing to 18.4% if the underwriters' option is exercised [14]. Company Overview - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in chronic inflammatory diseases, with its lead candidate currently in Phase 3 trials for ulcerative colitis [20].

Core Viewpoint - Abivax SA has announced the launch of a public offering of approximately $400 million, aimed at funding its clinical development and operational needs [1][10]. Group 1: Offering Details - The public offering will consist of American Depositary Shares (ADSs), each representing one ordinary share of the company, with a nominal value of €0.01 per share [1]. - The company plans to grant underwriters a 30-day option to purchase additional ADSs, up to 15% of the total number proposed to be sold [1]. - The offering price will be determined through a book-building process, and the final amount and terms will be announced after pricing [4][7]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to be allocated as follows: approximately 23% for the development of obefazimod for Ulcerative Colitis, approximately 5% for Crohn's Disease, and about 72% for working capital and general corporate purposes [10][14]. Group 3: Company Background - Abivax is a clinical-stage biotechnology company focused on developing therapeutics that modulate the immune response in patients with chronic inflammatory diseases [18]. - The lead drug candidate, obefazimod (ABX464), is currently in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis [18]. Group 4: Financial Position - As of June 30, 2025, the company had cash and cash equivalents of $71.4 million, which is expected to finance its operating cash flow requirements into the fourth quarter of 2025 [9].

Core Viewpoint - Pharvaris N.V. is planning to offer and sell $150 million of ordinary shares to fund research and development, hiring a sales and marketing team in the U.S., and for general corporate purposes [1] Group 1: Offering Details - Pharvaris intends to grant underwriters a 30-day option to purchase an additional $22.5 million of ordinary shares [1] - The offering is subject to market conditions, and there is no assurance regarding its completion or terms [1] - The shares are being offered under an effective shelf registration statement filed with the U.S. SEC [3] Group 2: Use of Proceeds - The net proceeds from the offering will primarily fund late-stage clinical programs, sales and marketing team hiring, and working capital [1] Group 3: Company Overview - Pharvaris is a late-stage biopharmaceutical company focused on developing oral bradykinin B2 receptor antagonists for bradykinin-mediated diseases [6] - The company aims to provide injectable-like efficacy and placebo-like tolerability with oral therapies for treating hereditary angioedema (HAE) [6] - Pharvaris is currently conducting pivotal Phase 3 studies for the prevention and on-demand treatment of HAE attacks [6]

Nasdaq-listed GameSquare announced the completion of a public offering of approximately $70 million and stated that the majority of the proceeds will be used to expand its ETH holdings, aiming to become one of the largest publicly listed holders of ETH. https://t.co/05HFgwX7Wq ...

Company Overview - LiveOne is a creator-first music, entertainment, and technology platform headquartered in Los Angeles, CA, focused on delivering premium experiences and content worldwide through memberships and live and virtual events [5] - The company's subsidiaries include Slacker, PodcastOne, PPVOne, Custom Personalization Solutions, LiveXLive, DayOne Music Publishing, Drumify, and Splitmind [5] Public Offering Announcement - LiveOne announced the commencement of an underwritten public offering of shares of its common stock, subject to market conditions [1] - Lucid Capital Markets is acting as the sole book-running manager for the offering, which is made pursuant to a shelf registration statement filed with the SEC [2] Regulatory Filings - A preliminary prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website [3]

Core Points - BriaCell Therapeutics Corp. announced a public offering of 12,000,000 units at a price of $1.25 per unit, aiming for gross proceeds of $15 million before expenses [1][3] - Each unit consists of one common share (or a Pre-Funded Warrant) and one Warrant, with the Warrant allowing the purchase of one common share at an exercise price of $1.50, expiring five years from issuance [1][3] - The offering is expected to close on July 16, 2025, subject to customary closing conditions [2] Financial Details - The net proceeds from the offering will be used for working capital, general corporate purposes, and advancing business objectives [3] - The offering is being facilitated by ThinkEquity as the sole placement agent [3] Regulatory Information - A registration statement on Form S-1 was filed with the SEC and became effective on July 15, 2025, with the offering being made only by means of a prospectus [4]

Core Viewpoint - Milestone Pharmaceuticals Inc. has announced a public offering of common shares and warrants, aiming to raise approximately $52.5 million to fund the clinical development and commercialization of its lead drug, etripamil, for treating paroxysmal supraventricular tachycardia (PSVT) [1][2]. Group 1: Offering Details - The public offering includes 31,500,000 common shares and accompanying Series A and Series B common warrants, priced at $1.50 per share and warrant [1]. - Additionally, pre-funded warrants to purchase 3,502,335 common shares are offered at a price of $1.499, which includes accompanying Series A and Series B common warrants [1]. - The offering is expected to close around July 14, 2025, pending customary closing conditions [1]. Group 2: Use of Proceeds - The net proceeds from the offering will be utilized alongside existing cash to support the clinical development and commercial launch of etripamil for PSVT, as well as for working capital and general corporate purposes [2]. Group 3: Company Background - Milestone Pharmaceuticals is focused on developing and commercializing innovative cardiovascular medicines, with a recent New Drug Application (NDA) submitted to the FDA for etripamil targeting PSVT [5].